Karolinska Institutet - Sweden
Team leader: Prof. Rolf Lewensohn, PhD, MD
Karolinska Institutet (KI) is one of Europe's largest, and one of the world's leading, medical universities. KI annually awards the Nobel Prize in Physiology or Medicine and accounts for 40 per cent of all medical academic research in Sweden. Research at KI has a strong European dimension, with almost 200 ongoing projects within the EU's Sixth Framework Programme and with a coordinating function in 28 of these projects. KI is also the major Swedish beneficiary of funds from the NIH. Prof. Lewensohn's research group is performing preclinical and translational cancer research at Karolinska Biomics Centre (KBC), which collaborates closely with the Karolinska University Hospital. KBC has in house 40 researchers that are operating high throughput technologies in drug screening, global gene expression and proteomic analysis. Preclinical and clinical KBC researchers run translational research projects related to therapy response in various tumor types, such as diagnostics and predictive factors, as well as screening and characterizing substances with antitumor activity.